Abstract:Management of moderate to severe pain relies heavily on opioid analgesics such as morphine, oxycodone, and fentanyl in clinics. However, their prolonged use was associated with undesirable side effects. Many new strategies to reduce side effects have been proposed, but not without disadvantages. Using a hot plate model as a phenotypic screening method, our studies identified (3R,4S)-9d with a new scaffold as a potent analgesic with ED50 values of 0.54 mg/kg and 0.021 mg/kg in hot plate and antiwrithing models, respectively. Mechanistic studies showed that it elicited its analgesic effect via the active metabolite (3R,4S)-10a. The mechanism of (3R,4S)-10a-induced activation of the μ opioid receptor (MOR) was proposed by means of molecular dynamics (MD) simulation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00722?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00722</a>.Active murine MOR, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_002.csv">CSV</a>)Screening of resolution of 4c; optimization of the resolution procedure of 4c; HPLC spectrum of 4c and its enantiomers; experimental and theoretical ECD; In vivo metabolism assay; potential energy and RMSD evolution during MD simulation; 1H NMR and 13C NMR spectra of final compounds; HPLC spectra of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_003.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives As Potent and Selective BET Inhibitors for the Management of Neuropathic Pain.

Discovery, Structure-Activity Relationship, and Mechanistic Studies of 1-((3R,4s)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one As a Novel Potent Analgesic.

Discovery, Structure–Activity Relationship, and Mechanistic Studies of 1-((3 R ,4 S )-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic

Discovery of a highly selective and potent kappa opioid receptor agonist from N-cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydro- northebaines with reduced central nervous system (CNS) side effects navigated by the message-address concept.

Discovery of 3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-n-phenylpiperidine-1-carboxamide As Novel Potent Analgesic.

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

Selective Activation of TASK-3-containing K+ Channels Reveals Their Therapeutic Potentials in Analgesia

Development of Tetrahydroquinoline-Based Inhibitors for Chronic Pain

Identification of (4-chlorophenyl)(5-hydroxynaphtho[1,2-b]furan-3-yl)methanone as novel COX-2 inhibitor with analgesic profile

Discovery and Analgesic Evaluation of 8-Chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione As a Novel Potent D-Amino Acid Oxidase Inhibitor.

A Novel Analgesic Isolated from a Traditional Chinese Medicine.

Novel dual-target μ‐opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management

Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.

Identification of N-(((1S,3R,5S)-adamantan-1-yl)methyl)-3-((4-chlorophenyl)sulfonyl)benzenesulfonamide as novel Nav1.8 inhibitor with analgesic profile

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain

Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders